Driven by Swiss Innovation and China’s Efficient Industrial Chain, Accelerating Global CRDMO Footprint

Bern, Switzerland / Taixing, Jiangsu, China – Space Peptides today announced the appointment of Dr. Guixian Hu as Chief Operating Officer (COO). Dr. Hu will join the company’s core leadership team, taking full responsibility for global operations, manufacturing technology, and integrated CRDMO execution, with a specific focus on strengthening Space Peptides’ development and manufacturing base in Taixing, Jiangsu. With Dr. Hu’s appointment, Space Peptides has successfully closed the strategic loop from front-end market development to back-end efficient delivery, formally establishing the “Market-Order-Delivery Iron Triangle” as its core management team. This marks the full formation of the company’s global operations management system.

Former Lonza Executives Unite, Bringing World-Class Expertise to the Core Management Team

Dr. Hu’s appointment marks a further leap forward for Space Peptides’ core executive team. Most notably, the company’s three current core leaders – Dr. Josef Schröer, Chief Commercial Officer; Sandy Huang, President of APAC; and newly appointed Chief Operating Officer Dr. Guixian Hu –  each possess deep experience as senior executives at Lonza, a global top-tier CDMO giant. The combined strength of these three industry veterans infuses Space Peptides with cutting-edge international biopharma management experience, Swiss-quality standards, and a gene of operational excellence. The “Iron Triangle” collaborative structure formed at the strategic level ensures world-class delivery standards for clients at every stage – from market development and order intake to final delivery.

Dr. Runze He, Chairman of Space Peptides, stated: “We are very pleased to welcome Dr. Guixian Hu to Space Peptides. The Taixing site facility is a critical part of achieving our global strategy. We not only have a powerful AI platform for innovative drug R&D, but we can also provide customers with one-stop CMC solutions, ensuring product quality meets regulatory requirements in China, the US, and Europe as our clients expand globally, while maintaining supply chain stability. With Dr. Josef Schröer advancing global CDMO commercial development in Europe and the US, Sandy Huang driving business development in Asia-Pacific, and Dr. Hu overseeing operations and manufacturing execution, together they have built a complete market-order-delivery platform for our global biopharma partners.”

Strategic Advantage: Deepening a Highly Competitive Differentiation Engine to Perfectly Combine Eastern and Western Strengths

Under the guidance of this new core management team, Space Peptides is deepening its highly competitive differentiation strategy engine, perfectly combining the strengths of East and West:

• Swiss Quality & Innovation: Switzerland is renowned for high-quality manufacturing, client IP protection, and sustainable development. Headquartered in Switzerland, Space Peptides has fully integrated its operations with the Swiss production quality system. Leveraging Switzerland’s deep heritage in life sciences and precision manufacturing, the company continuously absorbs top-tier R&D resources to drive breakthroughs and innovation in cutting-edge peptide technologies.

• China’s Industrial Chain Advantage: Space Peptides deeply integrates China’s mature, complete, and highly efficient biopharma supply chain and manufacturing system, particularly at its development and manufacturing base in Taixing, Jiangsu, to achieve high-quality, high-efficiency production output. Driven by Swiss source innovation and efficient Chinese implementation, the company has fully demonstrated this dual-driven approach in the field of global-leading AI-powered peptide drug discovery and development.

• Global Commercial Footprint: With a forward-looking strategic vision, Space Peptides deploys its world-class R&D and manufacturing capabilities across a global customer network, precisely responding to the dynamic needs of global markets.

Dr. Guixian Hu Leads Operations, Strengthening Global CRDMO Execution

As COO, Dr. Hu will help ensure that customer needs are efficiently transformed into technical evaluation, process development, scale-up, GMP manufacturing, and long-term supply. His extensive experience in advancing projects from lab development to commercial production will be central to enhancing process robustness, manufacturing readiness, and international customer delivery capabilities at the Taixing site.

Dr. Hu brings over 30 years of international pharmaceutical experience across China, Europe, and the United States. He holds a Ph.D. in Organic Chemistry from ETH Zurich and completed his postdoctoral research in process development and optimization at Lonza. His senior leadership roles at Lonza and Porton Pharma Solutions covered process development, CMC, GMP manufacturing, technology transfer, EHS, peptides, oligonucleotides, XDCs, flow chemistry, green chemistry, lab automation, and AI-enabled technology platforms.

“I am honored to join Space Peptides at this important stage of its global expansion,” said Dr. Hu. “I look forward to working with Josef, Runze, Sandy, and the broader team to build a technically strong, globally coordinated, and execution-driven CRDMO platform that creates long-term value for customers worldwide.”

Setting Sail Globally: Driven by the Iron Triangle, Defining a New Height for CRDMO

The addition of Dr. Guixian Hu and the formation of the “Executive Iron Triangle” mark a significant milestone in Space Peptides’ history. Moving forward, Space Peptides will continue to uphold its golden rule – “Swiss Quality & Innovation, China’s Industrial Chain Advantage, Global Commercial Footprint” – providing customers worldwide with exceptional services and products at world-class standards, ushering in a new era of high-quality development for the peptide and oligonucleotide CRDMO industry.

About Space Peptides

Space Peptides is a Swiss-headquartered global CRDMO company specializing in peptide and oligonucleotide discovery, development, and manufacturing services. The company integrates AI-enabled discovery, process development, GMP manufacturing, IP-conscious project governance, and global commercial execution to support pharmaceutical and biotechnology innovators worldwide.